Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia

References

• AubierMAldonsPMLeakATelithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitisRespir Med2002968627112418583
   PubMed Web of Science ®Google Scholar
• AventisKetek® (telithromycin) briefing document for the FDA anti-infective drug products advisory committee meeting [online]2003 Accessed 27 June 2005 URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf
   Google Scholar
• Aventis2005 Ketek® (telithromycin) tablets [package insert]. August.
   Google Scholar
• BanNNissenPHansenJThe complete atomic structure of the large ribosomal subunit at 2.4 A resolutionScience20002899052010937989
   PubMed Web of Science ®Google Scholar
• BarryALFuchsPCBrownSDIn vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzaeAntimicrob Agents Chemother1998422138409687424
   PubMed Web of Science ®Google Scholar
• BartlettJGDowellSFMandellLAPractice guidelines for the management of community-acquired pneumonia in adultsClin Infect Dis2000313478210987697
   PubMed Web of Science ®Google Scholar
• BébéarCMRenaudinHBryskierAComparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmasAntimicrob Agents Chemother2000441980210858366
   PubMed Web of Science ®Google Scholar
• Bemer-MelchiorPJuvinMETassinSIn vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factorsAntimicrob Agents Chemother2000442999300211036012
   PubMed Web of Science ®Google Scholar
• BermudezLEInderliedCBWuMActivities of ABT-773, telithromycin and linezolid against Mycobacterium avium (MAC) in vitro and in vivo [Abstract]2000Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and OxazolidinonesMarch 16, 2000Seville, Spain 03.16
   Google Scholar
• BerthoGGharbi-BenarousJDelaforgeMConformational analysis of ketolide, conformations of RU 004 in solution and bound to bacterial ribosomesJ Med Chem1998413373869719590
   PubMed Web of Science ®Google Scholar
• BhargavaVLenfantBPerretCLack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycinScand J Infect Dis200234823612578152
   PubMed Web of Science ®Google Scholar
• BhargavaVLeroyBShiJEffect of telithromycin on pharmacokinetics of theophylline in healthy volunteers [Abstract]2002Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 2002San Diego, CA, USA A-1832
   Google Scholar
• BiedenbachDJBarrettMSJonesRNComparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strainsDiagn Microbiol Infect Dis199831349539635909
   PubMed Web of Science ®Google Scholar
• BonnefoyAGirardAMAgouridasCKetolides lack inducibility properties of MLS(B) resistance phenotypeJ Antimicrob Chemother19974085909249208
   PubMed Web of Science ®Google Scholar
• BonnefoyAGuittonMDelachaumeCIn vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection modelsAntimicrob Agents Chemother20014516889211353612
   PubMed Web of Science ®Google Scholar
• BoswellFJAndrewsJMAshbyJPThe in-vitro activity of HMR 3647, a new ketolide antimicrobial agentJ Antimicrob Chemother199842703910052892
   PubMed Web of Science ®Google Scholar
• BoswellFJAndrewsJMWiseRPharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effectJ Antimicrob Chemother199841149539533455
   PubMed Web of Science ®Google Scholar
• BrownSDRybakMJAntimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US studyJ Antimicrob Chemother200454Suppl 1i71515265831
   PubMed Web of Science ®Google Scholar
• BuchananPPStephensTALeroyBA comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitisAm J Rhinol2003173697714750614
   PubMedGoogle Scholar
• CapobiancoJOCaoZShortridgeVDStudies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniaeAntimicrob Agents Chemother2000441562710817709
   PubMed Web of Science ®Google Scholar
• CarbonCMoolaSVelancsicsITelithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumoniaClin Microbiol Infect2003969170312925111
   PubMed Web of Science ®Google Scholar
• CarbonCvan RensburgDFogartyCFive- to 10-day therapy with telithromycin is effective in outpatients with pneumococcal bacteraemia associated with community-acquired pneumonia [Abstract]2003Abstracts of the 13th European Congress of Clinical Microbiology and Infectious DiseasesJune 2003Glasgow, UK P1129
   Google Scholar
• ChampneyWSToberCLStructure–activity relationships for six ketolide antibioticsCurr Microbiol2001422031011270656
   PubMed Web of Science ®Google Scholar
• CiervoCAShiJOutline Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infectionsCurr Med Res Opin20052116415016238904
   PubMed Web of Science ®Google Scholar
• DaviesTADewasseBEJacobsMRIn vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniaeAntimicrob Agents Chemother2000444141710639373
   PubMed Web of Science ®Google Scholar
• DouthwaiteSChampneySStructures of ketolides and macrolides determine their mode of interaction with the ribosomal target siteJ Antimicrob Chemother200148Suppl. T118
   Google Scholar
• DouthwaiteSMauvaisPChampneyWSStructure–activity relationship of the ketolide telithromycin (HMR 3647) [Abstract]2000Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and OxazolidinonesApril 2000Seville, Spain 02.02
   Google Scholar
• DuboisJSt-PierreCIntracellular activity and post-antibiotic effect of ABT-773 against Legionella [Abstract]2000Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and OxazolidinonesApril 2000Seville, Spain 02.33
   Google Scholar
• DunbarLMCarbonCvan RensburgDEfficacy of telithromycin in community-acquired pneumonia caused by atypical and intracellular pathogensInfect Dis Clin Pract2005131016
   Google Scholar
• EdlundCAlvanGBarkholtLPharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microfloraJ Antimicrob Chemother200046741911062193
   PubMed Web of Science ®Google Scholar
• FarrellDJFelminghamDActivities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003Antimicrob Agents Chemother2004481882415105150
   PubMed Web of Science ®Google Scholar
• FelminghamDFarrellDJIn vitro activity of telithromycin against Gram-negative bacterial pathogensJ Infect2006521788015996744
   PubMed Web of Science ®Google Scholar
• FergusonBJGuzzettaRVSpectorSLEfficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitisOtolaryngol Head Neck Surg20041312071415365537
   PubMed Web of Science ®Google Scholar
• Fernandez-RoblasRCalvoREstebanJThe bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistanceJ Antimicrob Chemother199943285911252337
   PubMed Web of Science ®Google Scholar
• FileTMJrStreptococcus pneumoniae and community-acquired pneumonia: a cause for concernAm J Med2004117Suppl 3AS3950
   PubMedGoogle Scholar
• FogartyCde WetRMandellLFive-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced healthcare resource utilizationChest20051281980816236845
   PubMed Web of Science ®Google Scholar
• FogartyCZervosMTellierGTelithromycin for the treatment of acute exacerbations of chronic bronchitisInt J Clin Pract2005b5929630515857326
   PubMed Web of Science ®Google Scholar
• FogartyCMPatelTCDunbarLMEfficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter studyBMC Infect Dis2005c54315927060
   PubMed Web of Science ®Google Scholar
• GehannoPSultanEPassotVTelithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomyInt J Antimicrob Agents200321441512727077
   PubMed Web of Science ®Google Scholar
• HagbergLTorresAvan RensburgDEfficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumoniaInfection2002303788612478329
   PubMed Web of Science ®Google Scholar
• HansenLHMauvaisPDouthwaiteSThe macrolide–ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNAMol Microbiol1999316233110027978
   PubMed Web of Science ®Google Scholar
• JenkinsSGFarrellDJPatelMTrends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000–2003: PROTEKT US years 1–3J Infect2005513556315950288
   PubMed Web of Science ®Google Scholar
• KhairOAAndrewsJMHoneybourneDLung concentrations of telithromycin after oral dosingJ Antimicrob Chemother2001478374011389116
   PubMed Web of Science ®Google Scholar
• KlugmanKPLonksJRHidden epidemic of macrolide-resistant pneumococciEmerg Infect Dis200511802715963272
   PubMed Web of Science ®Google Scholar
• KohnoSHobanDand the PROTEKT Surveillance Study GroupComparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999–2000)J Chemother2003153354112962361
   PubMed Web of Science ®Google Scholar
• KolarsJCSchmiedlin-RenPSchuetzJDIdentification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytesJ Clin Invest199290187181430211
   PubMed Web of Science ®Google Scholar
• LeclercqRResistance to ketolides: role of ribosomal modification and macrolide efflux [Abstract]2000Abstracts of the 40th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 2000Toronto, Canada 1135
   Google Scholar
• LeclercqRCourvalinPBacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modificationAntimicrob Agents Chemother199135126772 Erratum in: Antimicrob Agents Chemother, 35:2165.1929280
   PubMed Web of Science ®Google Scholar
• LorenzJRoscherKEfficacy and safety of telithromycin in 34,929 patients with respiratory tract infections [Abstract]2004Abstracts of the 44th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 2004Washington, DC, USA L-914
   Google Scholar
• LutermanMTellierGLaskoBEfficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitisEar Nose Throat J2003825768014503094
   PubMedGoogle Scholar
• MankinAXiongLKhaitovichPInteraction of macrolides and ketolides with the ribosome [Abstract]2000Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and OxazolidinonesApril 2000Seville, Spain 01.02
   Google Scholar
• Mathers DunbarLHassmanJTellierGEfficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adultsClin Ther200426486214996517
   PubMed Web of Science ®Google Scholar
• MauvaisPBonnefoyALack of in vitro MLSB resistance induction by the ketolide telithromycin (HMR 3647): role of the 3-keto group [Abstract]2000Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and OxazolidinonesApril 2000Seville, Spain 02.10
   Google Scholar
• MiyamotoNMurakamiSYajinKPharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology [Abstract]2000Abstracts of the 40th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 2000Toronto, Canada 2144
   Google Scholar
• MontayGShiJLeroyBBhargavaVEffects of telithromycin on the pharmacokinetics of digoxin in healthy men [Abstract]2002Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 2002San Diego, CA, USA A-1834
   Google Scholar
• MoutonYThamlikitkulVNiemanRBTelithromycin versus other first-line single-agent antibiotics in the treatment of community-acquired pneumonia: a randomized superiority trialClin Microbiol Infect Dis200511Suppl 2S267
   Google Scholar
• Muller-SerieysCAndrewsJVacheronFTissue kinetics of telithromycin, the first ketolide antibacterialJ Antimicrob Chemother2004531495714729764
   PubMed Web of Science ®Google Scholar
• Muller-SerieysCSolerPCantalloubeCBronchopulmonary disposition of the ketolide telithromycin (HMR 3647)Antimicrob Agents Chemother2001453104811600363
   PubMed Web of Science ®Google Scholar
• NamourFWesselsDHPascualMHPharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple dosesAntimicrob Agents Chemother200145170511120961
   PubMed Web of Science ®Google Scholar
• NiedermanMSChangJRStewartJComparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycinCurr Med Res Opin2004a2074956 Erratum in: Curr Med Res Opin 20:1331.15140342
   PubMed Web of Science ®Google Scholar
• NiedermanMSChangJRStewartJHospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trialsCurr Med Res Opin2004b209698015265241
   PubMed Web of Science ®Google Scholar
• NiedermanMSMcCombsJSUngerANThe cost of treating community-acquired pneumoniaClin Ther199820820379737840
   PubMed Web of Science ®Google Scholar
• NiedermanMSMcCombsJSUngerANTreatment cost of acute exacerbations of chronic bronchitisClin Ther1999215769110321424
   PubMed Web of Science ®Google Scholar
• NovotnyGWAndersenNMPoehlsgaardJTelithromycin interacts directly with the base of A752 in domain II of 23S ribosomal RNA, in contrast to erythromycin and clarithromycin [Abstract]2001Abstracts of the 11th European Congress of Clinical Microbiology and Infectious DiseasesJune 2001Istanbul, Turkey P480
   Google Scholar
• OdenholtILowdinECarsOPharmacodynamics of telithromycin in vitro against respiratory tract pathogensAntimicrob Agents Chemother20014523911120939
   PubMed Web of Science ®Google Scholar
• PankuchGAHoellmanDBLinGActivity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assayAntimicrob Agents Chemother199842303249797250
   PubMed Web of Science ®Google Scholar
• PankuchGAVisalliMAJacobsMRSusceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agentsAntimicrob Agents Chemother199842624309517943
   PubMed Web of Science ®Google Scholar
• PerretCLenfantBWeinlingEPharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteersChemotherapy2002482172312476037
   PubMed Web of Science ®Google Scholar
• Pham GiaHRoederVNamourFThe new ketolide, HMR 3647, achieves high and sustained concentrations in white blood cells in man [Abstract]J Antimicrob Chemother199944Suppl A57P79
   Google Scholar
• PullmanJChamplinJVroomanPSJrEfficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adultsInt J Clin Pract2003573778412846341
   PubMed Web of Science ®Google Scholar
• ReinertRRFelminghamDthe EU PROTEKT Study GroupSustained antimicrobial activity of telithromycin in Europe post-launch: the PROTEKT study (Years 1–4) [Abstract]2004Abstracts of the 44th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 2004Washington, DC, USA C2-813
   Google Scholar
• ReinertRRRodloffACHalleEAntibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the ketolide telithromycin: results from the PROTEKT surveillance study (1999–2000)Chemotherapy2004501435115272227
   PubMed Web of Science ®Google Scholar
• RobertsMCSutcliffeJCourvalinPNomenclature for macrolide and macrolide–lincosamide–streptogramin B resistance determinantsAntimicrob Agents Chemother19994328233010582867
   PubMed Web of Science ®Google Scholar
• RoblinPMHammerschlagMRIn vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniaeAntimicrob Agents Chemother1998421515169624507
   PubMed Web of Science ®Google Scholar
• RoosKBrunswig-PitschnerCKostricaREfficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitisChemotherapy200248100812011543
   PubMed Web of Science ®Google Scholar
• RoosKTellierGBazMClinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysisJ Infect2005502102015780415
   PubMed Web of Science ®Google Scholar
• RzeszutekMWierzbowskiAHobanDJA review of clinical failures associated with macrolide-resistant Streptococcus pneumoniaeInt J Antimicrob Agents2004249510415288306
   PubMed Web of Science ®Google Scholar
• SchitoGCMarcheseAElkharratDComparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance studyJ Chemother200416132215077994
   PubMed Web of Science ®Google Scholar
• SchlunzenFZarivachRHarmsJStructural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteriaNature20014138142111677599
   PubMed Web of Science ®Google Scholar
• ScholtzHESultanEWesselsDTelithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives [Abstract]2000Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and OxazolidinonesApril 2000Seville, Spain 09.29
   Google Scholar
• ShiJMontayGHardyPEffects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycinPharmacotherapy200525425115767219
   PubMed Web of Science ®Google Scholar
• ShiJPfisterMJenkinsSGPharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumoniaClin Pharmacokinet2005443172915762772
   PubMed Web of Science ®Google Scholar
• SultanENamourFMauriacCHMR 3647, a new ketolide antimicrobial, is metabolized and excreted mainly in feces in manJ Antimicrob Chemother199944Suppl A54
   Google Scholar
• SutcliffeJTait-KamradtAWondrackLStreptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux systemAntimicrob Agents Chemother1996401817248843287
   PubMed Web of Science ®Google Scholar
• Tait-KamradtADaviesTCronanMMutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passageAntimicrob Agents Chemother20004421182510898684
   PubMed Web of Science ®Google Scholar
• TellierGChangJRAscheCVComparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 daysCurr Med Res Opin2004207394715140341
   PubMed Web of Science ®Google Scholar
• TellierGNiedermanMSNusratRClinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumoniaJ Antimicrob Chemother2004545152315269191
   PubMed Web of Science ®Google Scholar
• van RensburgDJFogartyCKohnoSEfficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycinChemotherapy2005511869215980629
   PubMed Web of Science ®Google Scholar
• van RensburgDJMatthewsPALeroyBEfficacy and safety of telithromycin in community-acquired pneumoniaCurr Med Res Opin20021839740012487505
   PubMed Web of Science ®Google Scholar
• WatanukiYOdagiriSOguraTA new ketolide antibacterial, telithromycin, achieves high and sustained concentrations in sputum in patients [Abstract]2001Abstracts of the 22nd International Congress of ChemotherapyJune 2001Amsterdam, The Netherlands P9.007
   Google Scholar
• XiongLShahSMauvaisPA ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centreMol Microbiol199931633910027979
   PubMed Web of Science ®Google Scholar
• ZervosMJHeyderAMLeroyBOral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitisJ Int Med Res2003311576912870368
   PubMed Web of Science ®Google Scholar
• ZhanelGGJohansonCHisanagaTPharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant. Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrationsJ Antimicrob Chemother2004541072715531596
   PubMed Web of Science ®Google Scholar
• ZhanelGGJohansonCLaingNPharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mef(E)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs varyAntimicrob Agents Chemother2005491943815855517
   PubMed Web of Science ®Google Scholar